Compensated Cirrhosis Type C Market

Cirrhosis is scarring or fibrosis of the liver caused due to many types of liver diseases like chronic alcoholism and hepatitis. The liver carries out several functions, including detoxification of harmful substances body, cleaning the blood and making of the vital nutrients. Cirrhosis occurs in response to damage caused to your liver. Most common causes of Compensated liver cirrhosis are hepatitis B and C, diseases related to alcohol and NASH. Many chronic liver diseases develop gradually over time. The rate of progression of cirrhosis is usually slow in the early phases of the disease and then it accelerates after complications of cirrhosis arise. For the diagnosis of cirrhosis, liver biopsy is often required which provides information regarding the severity of the disease. Transient elastography (fibroscan) is a cost-effective technique for the screening of liver cirrhosis. Treatment for compensated cirrhosis should include treatment for HCV infection and can be treated by using direct antiviral agents. Diagnosis can be done by using esophagogastroduodenoscopy (EGD).
Compensated Cirrhosis Type C Market contains market size and forecasts of Compensated Cirrhosis Type C in Global, including the following market information:
Global Compensated Cirrhosis Type C Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Compensated Cirrhosis Type C market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Antagonist Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Compensated Cirrhosis Type C include Gilead Sciences, Inc., AbbVie Inc., Novartis International AG, Intercept Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Alnylam Pharmaceuticals Inc., Cadila Healthcare Ltd and Sanofi S.A, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Compensated Cirrhosis Type C companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Compensated Cirrhosis Type C Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Compensated Cirrhosis Type C Market Segment Percentages, by Type, 2021 (%)
Antagonist
Antiviral Drugs
Corticosteroids
Chelating Agents
Global Compensated Cirrhosis Type C Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Compensated Cirrhosis Type C Market Segment Percentages, by Application, 2021 (%)
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Drug Store
Global Compensated Cirrhosis Type C Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Compensated Cirrhosis Type C Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Compensated Cirrhosis Type C revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Compensated Cirrhosis Type C revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead Sciences, Inc.
AbbVie Inc.
Novartis International AG
Intercept Pharmaceuticals, Inc.
Novo Nordisk A/S
Eli Lilly and Company
Alnylam Pharmaceuticals Inc.
Cadila Healthcare Ltd
Sanofi S.A
Pfizer Inc.
Sun Pharmaceutical Industries Limited